Monica Sophie Cooper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Monica Sophie Cooper has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Giuliana C. Antolovich
Department of Neurodevelopment and Disability, The Royal Children’s Hospital, Melbourne, VIC 3052, Australia
7 shared publications Michael C. Fahey
Department of Paediatrics Monash University Melbourne Victoria Australia
4 shared publications- Adrienne Harvey
Medicine, Dentistry and Health Sciences University of Melbourne Parkville VIC Australia
3 shared publications Charuta Dagia
Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
3 shared publications- David J. Amor
Department of Paediatrics, The University of Melbourne, Melbourne, Australia
3 shared publications Dinah Reddihough
Department of Neurodevelopment & Disability, The Royal Children’s Hospital, Melbourne, Victoria, Australia
3 shared publications
Latest Publications
- 18 October 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Which Children Count? The Ethics of Selective Advocacy
- 18 October 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Which Children Count? The Ethics of Selective Advocacy
- Open Access
- 29 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Anterior Drooling Versus Posterior Drooling: A Comparative Analysis
Aims: To examine the patient population of a tertiary Interdisciplinary Saliva Control Clinic, describe management pathways and identify patients suitable for primary care. Methods: Retrospective single‐centre cohort study in a tertiary hospital reviewing patients referred to the Saliva Control Clinic over a 5‐year period. Results: Of 361 referrals, 289 patients were seen. Age at referral ranged from 4 months to 18 years, 8 months (median 4 years, 9 months). Most referrals were from General Paediatricians (163, 58.2%). Severe neurological impairment was the most common primary diagnosis (106, 36.7%). Anterior drooling alone was present in 233 patients (83.5%), with 46 (16.5%) having posterior involvement. Prior to clinic, the most common prior intervention was medication (103, 36.1%). Many children, mostly typically developing, required no treatment (71, 24.6%). Common interventions were medications (138, 47.8%), saliva‐specific surgery (74, 25.6%) and botulinum toxin (62, 21.5%). Saliva‐specific surgery was more likely in patients with posterior drooling (31, 67.4%) than anterior alone (40, 17.2%). Conclusion: Management of drooling depends on saliva flow and patient phenotype. Typically developing children usually require only reassurance. Anterior drooling in young children can be managed in primary care, while posterior drooling in children with neurodevelopmental disabilities should be prioritised for specialist care.
- 29 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
Open AccessAnterior Drooling Versus Posterior Drooling: A Comparative Analysis
Aims: To examine the patient population of a tertiary Interdisciplinary Saliva Control Clinic, describe management pathways and identify patients suitable for primary care. Methods: Retrospective single‐centre cohort study in a tertiary hospital reviewing patients referred to the Saliva Control Clinic over a 5‐year period. Results: Of 361 referrals, 289 patients were seen. Age at referral ranged from 4 months to 18 years, 8 months (median 4 years, 9 months). Most referrals were from General Paediatricians (163, 58.2%). Severe neurological impairment was the most common primary diagnosis (106, 36.7%). Anterior drooling alone was present in 233 patients (83.5%), with 46 (16.5%) having posterior involvement. Prior to clinic, the most common prior intervention was medication (103, 36.1%). Many children, mostly typically developing, required no treatment (71, 24.6%). Common interventions were medications (138, 47.8%), saliva‐specific surgery (74, 25.6%) and botulinum toxin (62, 21.5%). Saliva‐specific surgery was more likely in patients with posterior drooling (31, 67.4%) than anterior alone (40, 17.2%). Conclusion: Management of drooling depends on saliva flow and patient phenotype. Typically developing children usually require only reassurance. Anterior drooling in young children can be managed in primary care, while posterior drooling in children with neurodevelopmental disabilities should be prioritised for specialist care.
- 21 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 2086-2087
Comfort as Core Care in Therapeutic Advancements of Paediatric Neurology
- 21 September 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 2086-2087
Comfort as Core Care in Therapeutic Advancements of Paediatric Neurology
- Open Access
- 21 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1413-1425
Attitudes toward sodium valproate use, withdrawal, and counseling in people of reproductive potential: A scoping review
Regulatory restrictions and evolving clinical guidelines have aimed to reduce sodium valproate use in people of reproductive potential over the past decade due to its teratogenic risk. While clinical evidence and policy responses are well established, stakeholder perspectives remain less explored. This scoping review synthesizes the existing evidence on the attitudes of patients, caregivers and healthcare professionals regarding sodium valproate use, withdrawal and counseling in females of childbearing age. This scoping review, conducted according to JBI Methodology for a Scoping Review and registered on Open Science Framework ( https://doi.org/10.17605/OSF.IO/HK7QN ), analyzed studies which directly reported on, or measured, the attitudes of patients, caregivers and/or healthcare professionals regarding the use of sodium valproate for epilepsy in females. A structured search across four databases (EMBASE, Web of Science, MEDLINE, PsycINFO) and the gray literature was performed. A thematic synthesis of data was conducted to identify important themes and concepts. A total of 22 studies including 14 peer‐reviewed articles and 8 gray literature sources met the inclusion criteria, including only 2 qualitative studies. Most literature focused on patient and caregiver perspectives ( n = 15), with fewer addressing healthcare professional views ( n = 7). Methodology incorporating interviews ( n = 2) or free‐text survey responses ( n = 3) was uncommon. Across the studies, three key themes emerged: (i) patient disempowerment due to limited knowledge and suboptimal counseling and risk communication; (ii) the influence of maternal identity formation on attitudes, behaviors and decision‐making when navigating sodium valproate use; and (iii) concerns regarding regulatory responses, such as pregnancy prevention programs, particularly around implementation challenges, perceived paternalism and lack of individualized care. Published evidence on stakeholder attitudes toward sodium valproate use in people of reproductive potential remains limited. The existing literature highlights gaps in awareness, counseling, and patient‐centered delivery of pregnancy prevention programs. Future research should prioritize qualitative studies to better understand stakeholder attitudes and experiences to inform future guidelines and clinical practice. Plain Language Summary: Sodium valproate is an antiseizure medication that can harm an unborn baby when used during pregnancy. National and international programs have been introduced to reduce its use among people who could become pregnant. This review explored the perspectives of patients, caregivers and healthcare providers regarding sodium valproate use and withdrawal. Key themes included experiences of disempowerment relating to risk communication, the influence of maternal identity on treatment decisions and concerns about regulatory approaches. These findings highlight factors contributing to challenges with pregnancy prevention programs, in particular gaps in shared decision‐making, communication and patient‐centered care.
- 21 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1413-1425
Open AccessAttitudes toward sodium valproate use, withdrawal, and counseling in people of reproductive potential: A scoping review
Regulatory restrictions and evolving clinical guidelines have aimed to reduce sodium valproate use in people of reproductive potential over the past decade due to its teratogenic risk. While clinical evidence and policy responses are well established, stakeholder perspectives remain less explored. This scoping review synthesizes the existing evidence on the attitudes of patients, caregivers and healthcare professionals regarding sodium valproate use, withdrawal and counseling in females of childbearing age. This scoping review, conducted according to JBI Methodology for a Scoping Review and registered on Open Science Framework ( https://doi.org/10.17605/OSF.IO/HK7QN ), analyzed studies which directly reported on, or measured, the attitudes of patients, caregivers and/or healthcare professionals regarding the use of sodium valproate for epilepsy in females. A structured search across four databases (EMBASE, Web of Science, MEDLINE, PsycINFO) and the gray literature was performed. A thematic synthesis of data was conducted to identify important themes and concepts. A total of 22 studies including 14 peer‐reviewed articles and 8 gray literature sources met the inclusion criteria, including only 2 qualitative studies. Most literature focused on patient and caregiver perspectives ( n = 15), with fewer addressing healthcare professional views ( n = 7). Methodology incorporating interviews ( n = 2) or free‐text survey responses ( n = 3) was uncommon. Across the studies, three key themes emerged: (i) patient disempowerment due to limited knowledge and suboptimal counseling and risk communication; (ii) the influence of maternal identity formation on attitudes, behaviors and decision‐making when navigating sodium valproate use; and (iii) concerns regarding regulatory responses, such as pregnancy prevention programs, particularly around implementation challenges, perceived paternalism and lack of individualized care. Published evidence on stakeholder attitudes toward sodium valproate use in people of reproductive potential remains limited. The existing literature highlights gaps in awareness, counseling, and patient‐centered delivery of pregnancy prevention programs. Future research should prioritize qualitative studies to better understand stakeholder attitudes and experiences to inform future guidelines and clinical practice. Plain Language Summary: Sodium valproate is an antiseizure medication that can harm an unborn baby when used during pregnancy. National and international programs have been introduced to reduce its use among people who could become pregnant. This review explored the perspectives of patients, caregivers and healthcare providers regarding sodium valproate use and withdrawal. Key themes included experiences of disempowerment relating to risk communication, the influence of maternal identity on treatment decisions and concerns about regulatory approaches. These findings highlight factors contributing to challenges with pregnancy prevention programs, in particular gaps in shared decision‐making, communication and patient‐centered care.
- Open Access
- 2 July 2026
- Published by Wiley in Developmental Medicine & Child Neurology
Neuropathic pain in cerebral palsy and related genetic conditions: A scoping review of prevalence, characteristics, and management
Aim: To map existing evidence on neuropathic pain in cerebral palsy (CP) and related genetic conditions, including prevalence, descriptors, assessment methods, and management. Method: Following prospective registration, five databases (Ovid MEDLINE, Embase, CINAHL, Web of Science, Google Scholar) were searched in June 2025. The review followed the JBI framework and the PRISMA‐ScR guidelines. Eligible studies examined CP or associated genetic conditions and reported neuropathic pain. Data extraction and quality appraisal used Oxford Centre for Evidence‐Based Medicine levels and JBI checklists. Results: Twenty‐five studies met the inclusion criteria, all focused on CP, with no eligible studies on related genetic conditions. Most were low‐ to medium‐quality cross‐sectional studies or case reports. Prevalence varied widely. Only a few studies used validated screening tools such as PainDETECT or quantitative sensory testing. Common descriptors included burning, tingling, numbness, and allodynia, with several reports of postsurgical neuropathic pain. Impacts involved mobility changes and emotional distress. Management evidence was limited. Interpretation: Neuropathic pain appears in people with CP but remains poorly recognized and assessed. High‐quality studies with validated screening tools are needed to support earlier identification and improve care.
- 2 July 2026
- Published by Wiley in Developmental Medicine & Child Neurology
Open AccessNeuropathic pain in cerebral palsy and related genetic conditions: A scoping review of prevalence, characteristics, and management
Aim: To map existing evidence on neuropathic pain in cerebral palsy (CP) and related genetic conditions, including prevalence, descriptors, assessment methods, and management. Method: Following prospective registration, five databases (Ovid MEDLINE, Embase, CINAHL, Web of Science, Google Scholar) were searched in June 2025. The review followed the JBI framework and the PRISMA‐ScR guidelines. Eligible studies examined CP or associated genetic conditions and reported neuropathic pain. Data extraction and quality appraisal used Oxford Centre for Evidence‐Based Medicine levels and JBI checklists. Results: Twenty‐five studies met the inclusion criteria, all focused on CP, with no eligible studies on related genetic conditions. Most were low‐ to medium‐quality cross‐sectional studies or case reports. Prevalence varied widely. Only a few studies used validated screening tools such as PainDETECT or quantitative sensory testing. Common descriptors included burning, tingling, numbness, and allodynia, with several reports of postsurgical neuropathic pain. Impacts involved mobility changes and emotional distress. Management evidence was limited. Interpretation: Neuropathic pain appears in people with CP but remains poorly recognized and assessed. High‐quality studies with validated screening tools are needed to support earlier identification and improve care.
- 16 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2452-2466
Modified Delphi Study to Establish Consensus on an Australasian Minimum Data Set for Pediatric Stroke Rehabilitation
BACKGROUND: This study aimed to develop a consensus-derived minimum data set for childhood stroke and establish an agreed set of tools to measure key functional outcomes identified as important by childhood stroke survivors and their families. METHODS: A steering group from Australia and New Zealand comprising rehabilitation clinicians and families with lived experience was established to oversee the modified Delphi process. Online focus groups with parents and young people with lived experience determined key functional outcomes of importance to families throughout rehabilitation. Based on this information, a prospective survey-based modified Delphi process was conducted to reach consensus for an Australasian minimum data set for pediatric stroke rehabilitation. An advisory group comprising specialist rehabilitation clinicians from 9 rehabilitation services across Australia and New Zealand responded to 3 surveys, which aimed to reach consensus on the key functional outcomes that are important to measure, the tools to measure these outcomes, and the time points for measurement. After each survey, the steering group collated and analyzed the data, and confirmed the content of subsequent surveys. RESULTS: Seventy-three participants from 12 rehabilitation disciplines participated. After Survey 3, consensus was reached on the measures for 14 (64%) of 22 functional outcomes in the preschool age band, and 20 (50%) of the 40 potential measures in the school-aged band. The Canadian Occupational Performance Measure was identified as a particularly valuable tool, achieving broad consensus due to its clinical utility, flexibility, and alignment with outcomes of importance to families and clinicians. Agreement on tools to measure other functional outcomes, particularly body function outcomes, reached lower levels of consensus. CONCLUSIONS: The agreement on the best measurement tools to be included in a minimum data set represents an important advancement in pediatric stroke rehabilitation research. The current findings provide a foundation for transformative improvements in future research, and in the care of children recovering from stroke.
- 16 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2452-2466
Modified Delphi Study to Establish Consensus on an Australasian Minimum Data Set for Pediatric Stroke Rehabilitation
BACKGROUND: This study aimed to develop a consensus-derived minimum data set for childhood stroke and establish an agreed set of tools to measure key functional outcomes identified as important by childhood stroke survivors and their families. METHODS: A steering group from Australia and New Zealand comprising rehabilitation clinicians and families with lived experience was established to oversee the modified Delphi process. Online focus groups with parents and young people with lived experience determined key functional outcomes of importance to families throughout rehabilitation. Based on this information, a prospective survey-based modified Delphi process was conducted to reach consensus for an Australasian minimum data set for pediatric stroke rehabilitation. An advisory group comprising specialist rehabilitation clinicians from 9 rehabilitation services across Australia and New Zealand responded to 3 surveys, which aimed to reach consensus on the key functional outcomes that are important to measure, the tools to measure these outcomes, and the time points for measurement. After each survey, the steering group collated and analyzed the data, and confirmed the content of subsequent surveys. RESULTS: Seventy-three participants from 12 rehabilitation disciplines participated. After Survey 3, consensus was reached on the measures for 14 (64%) of 22 functional outcomes in the preschool age band, and 20 (50%) of the 40 potential measures in the school-aged band. The Canadian Occupational Performance Measure was identified as a particularly valuable tool, achieving broad consensus due to its clinical utility, flexibility, and alignment with outcomes of importance to families and clinicians. Agreement on tools to measure other functional outcomes, particularly body function outcomes, reached lower levels of consensus. CONCLUSIONS: The agreement on the best measurement tools to be included in a minimum data set represents an important advancement in pediatric stroke rehabilitation research. The current findings provide a foundation for transformative improvements in future research, and in the care of children recovering from stroke.
- Open Access
“What’s in It for the Kid?”: An Approach for the Bedside Ethicist
Background/Objectives: Advances in paediatric care have increased the survival of children with severe neurological impairment, often accompanied by complex disability, multimorbidity, and a substantial treatment burden. Determining whether interventions provide meaningful benefit to the child is ethically challenging, particularly when decision-making is shared between parents and clinicians, while the child has limited capacity to participate directly in decision-making. This paper examines the guiding question “what’s in it for the kid?” as a means of strengthening child-centred ethical deliberation alongside established frameworks. Methods: We undertook a conceptual bioethical analysis informed by clinical experience in an inner city tertiary public hospital. The analysis focuses on children with severe neurological impairment and medical complexity. The paper critically examines how the guiding question aligns with and extends key ethical constructs, including shared decision-making, the Zone of Parental Discretion, the Best Interests Standard, and care ethics. Clinical scenarios are used illustratively to demonstrate application in practice. Results: Existing ethical frameworks form an important foundational structure for complex decision-making. The question “what’s in it for the kid” translates ethical principles into a practical moral prompt that centres the child as the subject of decision-making. It facilitates clearer consideration of risks, benefits meaningful to the child and lived experience and helps to distinguish the child’s interests from those of parents and clinicians. Its simplicity enhances accessibility and supports consistent use in complex, high-stakes decisions. Conclusions: “What’s in it for the kid?” is a pragmatic and accessible ethical prompt that complements established frameworks by translating them into clinically usable practice. It promotes explicit, child-focused deliberation and supports a more transparent and child-centred evaluation of benefit and burden, particularly in contexts of uncertainty and medical complexity.
Open Access“What’s in It for the Kid?”: An Approach for the Bedside Ethicist
Background/Objectives: Advances in paediatric care have increased the survival of children with severe neurological impairment, often accompanied by complex disability, multimorbidity, and a substantial treatment burden. Determining whether interventions provide meaningful benefit to the child is ethically challenging, particularly when decision-making is shared between parents and clinicians, while the child has limited capacity to participate directly in decision-making. This paper examines the guiding question “what’s in it for the kid?” as a means of strengthening child-centred ethical deliberation alongside established frameworks. Methods: We undertook a conceptual bioethical analysis informed by clinical experience in an inner city tertiary public hospital. The analysis focuses on children with severe neurological impairment and medical complexity. The paper critically examines how the guiding question aligns with and extends key ethical constructs, including shared decision-making, the Zone of Parental Discretion, the Best Interests Standard, and care ethics. Clinical scenarios are used illustratively to demonstrate application in practice. Results: Existing ethical frameworks form an important foundational structure for complex decision-making. The question “what’s in it for the kid” translates ethical principles into a practical moral prompt that centres the child as the subject of decision-making. It facilitates clearer consideration of risks, benefits meaningful to the child and lived experience and helps to distinguish the child’s interests from those of parents and clinicians. Its simplicity enhances accessibility and supports consistent use in complex, high-stakes decisions. Conclusions: “What’s in it for the kid?” is a pragmatic and accessible ethical prompt that complements established frameworks by translating them into clinically usable practice. It promotes explicit, child-focused deliberation and supports a more transparent and child-centred evaluation of benefit and burden, particularly in contexts of uncertainty and medical complexity.
- Open Access
- 12 May 2026
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 68 (11) , 1492-1493
Long‐term respiratory support in cerebral palsy: Defining benefit beyond physiological change
Click on the article title to read more.
- 12 May 2026
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 68 (11) , 1492-1493
Open AccessLong‐term respiratory support in cerebral palsy: Defining benefit beyond physiological change
Click on the article title to read more.
- 21 January 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (1) , e70126
Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data
Objectives: To assess the frequency of valproate prescribing for female patients of childbearing age at the Royal Children's Hospital, Melbourne, and to assess the frequency of documented discussions with these patients about the teratogenicity of valproate and the discussions or prescribing of contraception. Study Design: Retrospective audit of hospital electronic medical records data; analysis of Pharmaceutical Benefits Scheme (PBS) valproate dispensing data. Setting, Participants: 13‐ to 18‐year‐old girls or women prescribed valproate at the Royal Children's Hospital, Melbourne during 29 May 2022–29 May 2024; PBS valproate dispensing data for Australia for the 2023 calendar year. Main Outcome Measures: Characteristics of adolescent female patients prescribed valproate; documented discussions of valproate‐related teratogenicity, and discussions or prescribing of contraception; population valproate prescribing rates for Australia and by state. Results: Valproate was prescribed for 245 female patients aged 13–18 years during 2022–2024 (median age, 16 years; interquartile range [IQR], 14–17 years); the median prescribed daily dose was 600 mg (IQR, 400–800 mg; range, 200–2000 mg). Valproate was prescribed for treating epilepsy for 221 patients (90%), including 97 (44%) with drug‐resistant epilepsy; 160 patients (65%) had neurodevelopmental disabilities. Teratogenicity was discussed with 32 patients (13%), less frequently with patients with a neurodevelopmental disability (9% vs. 20%; odds ratio [OR], 0.41; 95% confidence interval [95% CI], 0.19–0.88). Contraception was discussed with 69 patients (28%); the proportion was larger for patients with neurodevelopmental disabilities (34% vs. 16%; OR, 2.66; 95% CI, 1.37–5.14). Contraception was prescribed for 50 patients (20%); the proportion was larger for patients with neurodevelopmental disabilities (25% vs. 12%; OR, 2.50; 95% CI, 1.18–5.30). The national PBS‐subsidised dispensing rate during 2023 was 621 per 100,000 girls and women aged 13–18 years; in Victoria it was 556 per 100,000 girls and women aged 13–18 years. Conclusion: Despite the risk of teratogenicity, valproate was prescribed for a considerable number of female adolescents at the Royal Children's Hospital during 2022–2024 and across Australia during 2023. Its teratogenicity was discussed with few patients, nor were discussions or prescribing contraception frequent. Contraception was more frequently discussed and prescribed for patients with neurodevelopmental disability, but teratogenicity was discussed less often.
- 21 January 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (1) , e70126
Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data
Objectives: To assess the frequency of valproate prescribing for female patients of childbearing age at the Royal Children's Hospital, Melbourne, and to assess the frequency of documented discussions with these patients about the teratogenicity of valproate and the discussions or prescribing of contraception. Study Design: Retrospective audit of hospital electronic medical records data; analysis of Pharmaceutical Benefits Scheme (PBS) valproate dispensing data. Setting, Participants: 13‐ to 18‐year‐old girls or women prescribed valproate at the Royal Children's Hospital, Melbourne during 29 May 2022–29 May 2024; PBS valproate dispensing data for Australia for the 2023 calendar year. Main Outcome Measures: Characteristics of adolescent female patients prescribed valproate; documented discussions of valproate‐related teratogenicity, and discussions or prescribing of contraception; population valproate prescribing rates for Australia and by state. Results: Valproate was prescribed for 245 female patients aged 13–18 years during 2022–2024 (median age, 16 years; interquartile range [IQR], 14–17 years); the median prescribed daily dose was 600 mg (IQR, 400–800 mg; range, 200–2000 mg). Valproate was prescribed for treating epilepsy for 221 patients (90%), including 97 (44%) with drug‐resistant epilepsy; 160 patients (65%) had neurodevelopmental disabilities. Teratogenicity was discussed with 32 patients (13%), less frequently with patients with a neurodevelopmental disability (9% vs. 20%; odds ratio [OR], 0.41; 95% confidence interval [95% CI], 0.19–0.88). Contraception was discussed with 69 patients (28%); the proportion was larger for patients with neurodevelopmental disabilities (34% vs. 16%; OR, 2.66; 95% CI, 1.37–5.14). Contraception was prescribed for 50 patients (20%); the proportion was larger for patients with neurodevelopmental disabilities (25% vs. 12%; OR, 2.50; 95% CI, 1.18–5.30). The national PBS‐subsidised dispensing rate during 2023 was 621 per 100,000 girls and women aged 13–18 years; in Victoria it was 556 per 100,000 girls and women aged 13–18 years. Conclusion: Despite the risk of teratogenicity, valproate was prescribed for a considerable number of female adolescents at the Royal Children's Hospital during 2022–2024 and across Australia during 2023. Its teratogenicity was discussed with few patients, nor were discussions or prescribing contraception frequent. Contraception was more frequently discussed and prescribed for patients with neurodevelopmental disability, but teratogenicity was discussed less often.